ELLIOTT-ADVISORS-UK
8.1.2020 08:32:06 CET | Business Wire | Press release
Funds advised by Elliott Advisors (UK) Limited (together “Elliott”), that collectively hold an economic interest in Altran Technologies SA (“Altran” or the “Company”) representing nearly 14% of the share capital, today published a letter outlining their concerns with Capgemini SE’s (“Capgemini”) offer for Altran (“the Offer”).
Elliott believes that recent developments have underscored its current intention to not tender into an Offer that fails to recognise Altran’s true value.1 Elliott’s open letter to shareholders includes the following key points:
- Capgemini’s Offer Is Inadequate. The current Offer is the result of a suboptimal process driven by a series of corporate governance shortcomings. We consider that the Offer price of €14.00 per share does not reflect Altran’s true value and implies that shareholders are expected to forgo nearly all the upside potential of this combination.
- Offer is Now Worse: The Implied Premium Is Shrinking. The equity market has gone up in value since the Offer was announced in June, yet the Offer price has remained unchanged. Based on analysts’ consensus break price, the premium offered to shareholders today is only 7% , which is significantly below the 38% offered in comparable precedent transactions.2 Furthermore, key shareholders and market participants have expressed increasingly negative sentiment towards the Offer price.3
- More Pathways to Realise Value; Fewer Reasons to Tender Now. In Elliott’s view, there is no compelling case for tendering now given (1) the potential mid-term upside in shares of an independent Altran if the Offer fails compared to the currently inadequate Offer price,4 and (2) if the Offer succeeds, the incremental potential upside that could accrue to minority shareholders alongside Capgemini resulting from the synergy potential of the combination. Furthermore, should the Offer succeed, Capgemini’s commitments to reopen or refile the Offer after the Paris Court of Appeals decision in March in principle create the potential for additional optionality for remaining Altran shareholders.
Elliott continues to urge Capgemini to properly recognise the true value of this transformative combination. Elliott is convinced that a fair price would result in a win-win scenario for both Altran and Capgemini shareholders, and prevent further uncertainty and integration delay. In the meantime, Elliott believes all Altran shareholders should be well-informed of the options available to them, particularly in light of Capgemini’s binding commitments should the Offer succeed.
Elliott’s letter, along with additional analysis and perspectives, are available to view and download at www.FairValueforAltran.com . Interested parties are encouraged to visit the website to receive additional information and sign up for future updates.
About Elliott
Elliott Management Corporation manages approximately $40.2 billion of assets. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, high net worth individuals and families, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation.
1 Elliott's declarations of intent can be found on the AMF's website under the following references: D&I 220C0024 (3 January 2020); D&I 219C2705 (12 December 2019); D&I 219C2175 (5 November 2019); D&I 219C1736 (27 September 2019); D&I 219C1733 (26 September 2019); D&I 219C1630 (18 September 2019); D&I 219C1158 (12 July 2019). As stated in its declarations of intent, Elliott’s final intention will be determined at the end of the Offer period and promptly disclosed in accordance with the applicable regulation following its determination. |
2 “Break price” constitutes analysts’ estimate of the level at which Altran shares would trade should the Offer fail. Consensus break price corresponds to the average of break prices of event-driven brokerage research and commentary from Churchill, Olivetree, United First Partners, Investec, Market Securities, and Manolo from 4 December 2019 to 6 January 2020. List of comparable precedent transactions and further analysis can be found on page 12 of Elliott’s ‘Fair Value for Altran’ presentation published on 27 November 2019, available at www.FairValueForAltran.com . |
3 Examples of negative sentiment can be found on page 3 of Elliott’s Open Letter To Shareholders published today, available at www.FairValueForAltran.com . |
4 Illustrative mid-term value creation potential can be found on page 16 of Elliott’s ‘Fair Value for Altran’ presentation published on 27 November 2019, available at www.FairValueForAltran.com . |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107006138/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
